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Abstract
Kinesin-5 (also known as Eg5, KSP and Kif11) is required for assembly of a bipolar mitotic spindle. Small molecule inhibitors
of Kinesin-5, developed as potential anti-cancer drugs, arrest cell in mitosis and promote apoptosis of cancer cells. We
performed a genome-wide siRNA screen for enhancers and suppressors of a Kinesin-5 inhibitor in human cells to elucidate
cellular responses, and thus identify factors that might predict drug sensitivity in cancers. Because the drug’s actions play
out over several days, we developed an intermittent imaging screen. Live HeLa cells expressing GFP-tagged histone H2B
were imaged at 0, 24 and 48 hours after drug addition, and images were analyzed using open-source software that
incorporates machine learning. This screen effectively identified siRNAs that caused increased mitotic arrest at low drug
concentrations (enhancers), and vice versa (suppressors), and we report siRNAs that caused both effects. We then classified
the effect of siRNAs for 15 genes where 3 or 4 out of 4 siRNA oligos tested were suppressors as assessed by time lapse
imaging, and by testing for suppression of mitotic arrest in taxol and nocodazole. This identified 4 phenotypic classes of
drug suppressors, which included known and novel genes. Our methodology should be applicable to other screens, and the
suppressor and enhancer genes we identified may open new lines of research into mitosis and checkpoint biology.
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Introduction
Kinesin-5 (also known as Kif-11, Eg5 and KSP), is a plus-end-
directed, tetrameric motor protein required for establishing spindle
bipolarity during mitosis [1–4]. The first small molecule Kinesin-5
inhibitor (K5I) was identified in a cell-based screen for mitotic
arrest[5]. Potent and specific K5Is were then developed in the
hope of anti-cancer drugs that were as effective as Vinca alkaloids
and taxanes, but lacked their neurotoxicity [6]. Cancer cells
treated with K5Is arrest in mitosis with a monopolar spindle, and
subsequently undergo cell death by the intrinsic apoptosis pathway
[7]. Although all cancer cell lines tested arrest in mitosis when
treated with K5Is, the fraction of cells that undergo apoptosis
varies greatly for unexplained reasons [8–10]. In clinical trials, as
hoped, K5Is do not cause neurotoxicity, but they do cause severe
bone marrow toxicity, and it is not yet clear which patients, if any,
will benefit from treatment [6]. To facilitate success of these drugs,
it will be necessary to discover effective combination therapies,
and/or identify particular cancer genotypes that respond well.
This will require deeper understanding of cell responses. To this
end, we sought to identify genes for which partial or full loss of
function makes cells either more resistant (suppressors) or more
sensitive (enhancers) to drug treatment.
RNA interference (RNAi) technology provides an efficient
strategy to systematically test the role of individual genes in the
response of live cells or model organisms to drug treatments
[11–13]. However, most RNAi screens in human or Drosophila
cells have used assays where cells are fixed or lysed at a certain
time point to obtain a readout, which limits the amount of data
that can be obtained. RNAi screens with live cell imaging readouts
have been reported [14], but these require complex equipment
and analysis software. Here, we report a simple intermittent live
cell imaging method for scoring cell cycle and cell death
phenotypes in living cells, and its use to find suppressors and
enhancers of a Kinesin-5 inhibitor. We used this method to screen
a library of siRNAs targeting the full human genome, and further
characterized the strongest suppressors using time-lapse imaging.
We found several expected genes, and others that may reveal new
cellular systems involved in how the mitotic spindle responds to
drug perturbation.
Methods
Cell culture
HeLa H2B-GFP cells [15] were grown at 37uCu n d e r5 %C O 2
in Dulbecco’s Modified Eagle Medium supplemented with 10%
fetal calf serum and 1% penicillin streptomycin (Gibco). The
doubling time of this HeLa H2B-GFP cell line is approximately
18 hours. Cells were grown to 80–90% confluency in 75 cm
2
flasks and passaged every two days. Cells were frozen down in
multiple aliquots at passage 3 to 7, and stored in liquid nitrogen
until use. Only cells with passage numbers less than 15 were used
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plated in 384 well plates (Corning) using a Matrix WellMate.
Under these conditions the cells reach 60–70% confluency after
24 hours.
Human Genome siRNA Libraries
Two Dharmacon siRNA SMARTpool libraries were used for
primary screening. Both were arrayed such that each library well
contained one pool of four siRNA duplexes directed against one
gene. A smaller library of 509 SMARTpools that covered most of
the kinases in the human genome (Dharmacon siARRAY siRNA
Kinases Library Thermo Fisher Scientific, Lafayette, CO) was
provided as a generous gift by Pfizer Inc. (Groton CT) and was
originally obtained from Dharmacon in the late fall of 2004. This
was used mainly to optimize procedures, though we did recover
some kinases as enhancer hits. A full human genome library of
21,121 siRNA SMARTpools, (Dharmacon siARRAY siRNA
Library, Human Genome, G-005000-05, Thermo Fisher Scien-
tific, Lafayette, CO) was obtained by the Harvard Medical School
ICCB-Longwood Screening Facility in 2006. This was used for the
full genome screen.
All library stocks were made up in 1x Dharmacon Buffer
(20 mM KCl, 6 mM HEPES-pH 7.5, 0.2 mM MgCl2), trans-
ferred to twin.tec 384-well PCR plates (Eppendorf), sealed with
PlateLoc Thermal Seals (Velocity-11), and stored at 220C.
Concentrated Master Stocks of the siRNA libraries are stored at
10 uM or 20 uM. Aliquots from the Master Stocks were diluted in
1x Dharmacon Buffer to make 1 uM Screening Stocks of the
libraries, which were also stored in twin.tec 384-well plates at
220C.
Control siRNAs were plated in duplicate in each library plate.
Polo-like kinase 1 (PLK1, Dharmacon M-003290-01) was used as
a positive control for mitotic arrest and apoptosis. Negative
controls included siCONTROL #2(Dharmacon D-001206-13-05)
non-targeting siRNA and siGLO RISC-Free siRNA (Dharmacon
D-001220-01-05) to control for non-sequence-specific effects. A
diagram of the plate layout for a typical ICCB-Longwood siRNA
library stock plate is shown in Figure 1A.
Re-testing of primary screening positives was carried out using
the four individual siRNA duplexes that comprise each siRNA
SMARTpool. For initial confirmation, these duplexes were
obtained from the ICCB-Longwood human genome siRNA
duplex library (Dharmacon Human Genome siRNA Library,
Thermo Fisher Scientific, Lafayette, CO, obtained in 2006), which
comprises the approximately 84,000 individual siRNA duplexes
corresponding to the 21,121 human genome SMARTpools.
Individual duplexes are stored in Master Stocks at 10 uM or
20 uM, and in Cherry Pick Stocks at 1 uM, in twin.tec 384-well
plates. Duplexes were picked from Cherry Pick Stock plates using
an EVO75 (Tecan) liquid handler served by a BenchCel plate
stacker (Velocity11) and arrayed in cherry pick source plates for
screening. A diagram of the cherry pick plate layout used in both
the enhancer and suppressor screens is shown in Figure 1B.
Screening Protocol
Figure 2 shows a flowchart of the screening protocol. Screens of
SMARTpool libraries for the primary screens and of selected
individual duplexes for secondary screens were carried out
following essentially the same protocol, except for the transfection
step and the statistical analysis of each plate, as noted below.
Figure 1. siRNA library and cherry pick source plate layouts. (A) siRNA library pools were plated in twin.tec 384 well plates with controls in
column 3 (see key). (B) A typical cherry pick source plate for the KI5 enhancer and suppressor screens. Individual duplexes were plated randomly (one
duplex per well) in twin.tec 384 well plates so that duplexes targeting the same gene were unlikely to lie adjacent to each other. The edge wells (two
outside rows and two outside columns) were left empty in each cherry pick source plate. Control siRNA duplexes were plated in columns 20–22 (see
key). (C) Heat map of enhancer screen plate after 48 hours using ratios of monopolar spindles to interphase cells; wells with a higher ratio are
displayed as warmer colors (yellow), allowing visual identification of potential hits (D) Heat map of suppressor screen plate using ratios of monopolar
spindles to total object count; the cooler color (blue) indicates a positive well. (E) Heat map showing an extreme example of edge effects in a sample
plate from the enhancer screen.
doi:10.1371/journal.pone.0007339.g001
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Cells were reverse transfected with each siRNA SMARTpool at a
final concentration of 24 nM using HiPerFect transfection reagent
(Qiagen). Automated transfections were carried out in a Bioprotect
II biosafety cabinet (Baker) using a Velocity11 Bravo liquid handler
for pipeting. A Wellmate (Matrix) was used for plate filling. Each
siRNA pool was diluted to 429 nM by mixing 3 ul of 1 uM siRNA
Screening Stock with 4 ul of OptiMEM I Reduced Serum Medium
1x (Invitrogen) in an intermediate 384-well twin.tec plate. Next, 3 ul
of each diluted siRNA pool was added to 9.6 ul of OptiMEM and
0.4 ul of HiPerFect transfection reagent previously plated in each
well of in a black, clear bottom-384 well assay plate (Corning).
Transfection reagent and siRNAs were allowed to complex at room
temperature for 10 minutes. HeLa H2B GFP cells (2500 cells per
well in 40 uL of DMEM) were then added to the HiPerFect +
siRNAcomplexesandincubatedat37uCand5%CO2for24 hours.
siRNAs targeting the genes KIF11 and TTK were used as
positive controls in the enhancer and suppressor screens,
respectively. Negative controls included Dharmacon siCONTROL
Non-targeting siRNA #1, #2, #3, and #4 (Thermo Fisher
Scientific catalogue numbers D-001210-01-05, D-001210-02-05,
D-001210-03-05, D-001210-04-05) to control for non-sequence
specific events and Dharmacon siGLO RISC-free siRNA
(Thermo Fisher Scientific) as a transfection control.
siRNA transfection—Individual duplexes for secondary
screening
Cells were transfected with individual siRNA duplexes at a final
concentration of 18 nM using HiPerFect transfection reagent,
following a reverse-transfection protocol. Control siRNAs were
plated in sextuplicate in each assay plate in Columns 20–23 as
shown in Figure 1B. With the exception of these changes in siRNA
concentration and plate layout, transfection of individual duplexes
was carried out with the same protocol as the primary screen.
Kinesin-5 Inhibitor Treatment
EMD534085, a potent and specific small molecule Kinesin-5
inhibitor (K5I) that targets the mitotic kinesin Eg5/KIF11 was
used in this study[8,9]. The biological effects of this K5I are similar
to that of previously described potent and specific Kinesin-5
inhibitors[3,7,9]. Cells were imaged 24 hours after transfection to
provide baseline data on cell density. After imaging, the
transfection mix/media was removed by aspiration with a 24
channel straight manifold (Drummond Scientific) and replaced
with 50 uL of fresh media (Dulbecco’s Modified Eagle Medium
with 10% fetal calf serum and 1% penicillin streptomycin)
containing 60 nM K5I for the enhancer screen or 1 uM K5I for
the suppressor screen. After addition of K5I, cells were incubated
for an additional 48 hours and imaged for phenotypic changes at
24 hour intervals.
Microscopy
Images were acquired on an ImageXpress Micro high content
screening microscope (MDS Analytical Technologies, formerly
Molecular Devices) with a Photometrics CoolSNAP ES digital
CCD camera and a 20x Plan Fluor ELWD objective. Four single
wavelength GFP images (488 nm excitation, FITC filter cube,
Semrock) were taken in each well to capture 200–600 cells per
Figure 2. Schematic of primary screen assay protocol. Day 1: HeLa H2B GFP cells are transfected with siRNAs. Day 2: 24 hours after transfection,
cells are imaged using a screening microscope. Transfection mix is removed, and media containing 60 nM Kinesin 5 inhibitor (K5I; Enhancer screen) or
1 uM K5I (Suppressor screen) is added. Days 3 and 4: 48 and 72 hours after transfection, cells are imaged to monitor phenotypic changes.
doi:10.1371/journal.pone.0007339.g002
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environmental chamber was used with the ImageXpress Micro.
Assay plates were kept in the incubator until imaging time and
transported to the microscope in an insulated bag. On average,
each assay plate was imaged at room temperature for 20 minutes
every 24 hours. Samples were illuminated for 100 ms per image to
obtain the optimal signal to noise ratio for automated phenotyp-
ing. The 100 ms imaging time at 488 nm is not long enough to
significantly damage cells, as cell damage typically occurs at high
intensities of Ultraviolet radiation (350 nm) [2,16]. Each well was
imaged at 3 time points: the 24H Image was taken 24 hours after
transfection and before K5I addition in order to obtain a baseline
cell count for each siRNA condition. The 48H and 72H Images
were taken 48 hours and 72 hours after transfection.
Image Analysis
We analyzed acquired images with CellProfiler, an open-source
image-analysis package [17]. For image segmentation, we applied
a modified version of the Ridler-Calvard method [18] (referenced
as the Adaptive Ridler-Calvard in CellProfiler) to determine the
threshold. This method takes into account the threshold variation
across the image. Although the nuclei are evenly dispersed in most
images, clustered nuclei occasionally appear. Therefore a second
step was taken to divide the clustered objects using a watershed
segmentation[19], and all cells bordering the edge of images were
discarded. Over 80 different shape, intensity and texture features
were measured for each cell.
Each nucleus was classified as interphase, monopolar, or
‘‘other’’ (neither interphase nor monopolar). For phenotypic
classification, we took a machine learning approach using
CellProfiler Analyst, an extension of CellProfiler [20,21]. For
each phenotype, an initial training set was manually built. About
1000 cells were randomly retrieved from the entire dataset in
batches and manually sorted into positive and negative training
sets until training process reached convergence.
Heat maps were used to visualize the data for quality control
purposes. For the enhancer screen, heat maps were plotted for the
ratio of cells in monopolar arrest to cells in interphase. Wells with
a higher ratio are displayed as warmer colors (yellow, in
Figure 1C), allowing us to identify potential hits, and also to
assess potential plating artifacts. Heat maps for the suppressor
screen were plotted using the ratio of monopoles to total objects,
since these data included more cells with abnormal nuclei that
were not clearly scored as interphase. A cooler color (blue,
Figure 1D) indicates a positive well. Plotting heat maps also
allowed us to see artifacts resulting from edge effects or uneven
plating (e.g. see Figure 1E for an extreme example) that could be
corrected in analysis.
Statistical Analysis of Imaging Data from Primary Screen
Both interphase and monopolar cells were classified and
counted at 48 hours and 72 hours after transfection. The
phenotypic counts were used to calculate enhancer or suppressor
scores for each well, which were then ranked to identify the
siRNA pools that were positive in each assay. An evaluation of
the total cell count in each well at 24 hours was also included in
the score formula to eliminate wells with extremely low cell
density.
Enhancer Screen. For an siRNA to score as positive in the
enhancer screen, it must cause a significant increase in the ratio of
monopolar to interphase nuclei (color-coded as red and yellow
objects in Figures 3 and 4) at 48 and 72 hour time points relative
to the population average in a single experiment. A single
experiment consists of all plates transfected on the same day. The
large experiment-to-experiment variation makes the comparison
across the whole genome dataset biased towards the experiments
with higher transfection efficiency and lower toxicity.
The enhancer score is defined as
ScoreE~MAX r48hr
m=i ,r72hr
m=i
  
|fC 24hr
t
  
Where fC 24hr
t
  
~
1, if C24hr
t w cut-off
0, if C24hr
t ƒ cut-off
()
:
r48hr
m=i and r72hr
m=i are the monopolar to interphase nuclei ratios at the
48 and 72 hour time points. The value fC 24hr
t
  
is added to
discard wells with significantly low starting cell densities,
characterized by the total cell count at the 24 hour time point,
C24hr
t (24H Image). The cut-off for this step function was
arbitrarily chosen to be two standard deviations below the mean
of the population. The resulting enhancer score is directly
proportional to siRNA effectiveness in enhancing cell response
to K5I.
Suppressor Screen. For an siRNA to score as positive in the
suppressor screen, there must be a significantly lower percentage
of monopolar arrested nuclei at 48 and 72 hours after transfection.
Due to the high ratio of drug-induced apoptosis in the suppressor
screen, fragments of DNA from dead cells often float on top of
healthy interphase nuclei. Hence, we used a monopole to total
nuclei count ratio to calculate the suppressor score. All statistics
were calculated relative to population average of cells imaged at
the same time points from the same experiment.
The suppressor score is defined as
ScoreS~
s1
median s1 ðÞ
z
s2
median s2 ðÞ
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t
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where s1~exp
p1
mean p1 ðÞ {2|std p1 ðÞ
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mean p2 ðÞ z2|std p2 ðÞ
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{1
  
,
and p1~MAX r48hr
m=t ,r72hr
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,
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:
The r48hr
m=t and r72hr
m=t terms are the monopolar to total nuclei
count ratios at the 48 and 72 hour time points. The values r
48=24
i
and r
72=24
i characterize the cell survival rate and represent the ratio
of interphase nuclei at the 48 and 72 hours in relation to the
24 hour time point. Both p1 and p2 are exponentially rescaled and
normalized before addition to give the suppressor score. The
fC 24hr
t
  
step function was also introduced in the suppressor
screen, discarding wells with low cell density. The suppressor score
is inversely proportional to siRNA effectiveness in suppressing cell
response to K5I.
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Screens—Individual duplexes
For re-testing potential hits in secondary screens, a new baseline
was established to account for enrichment of positively scoring
wells. Multiple non-targeting siRNA oligos were placed as negative
controls on each cherrypick source plate (Figure 1B). The resulting
data was used to calculate the mean and standard deviation for
negative controls. We observed a large variation within the
negative controls in the enhancer screen for unknown reasons,
presumably related to the threshold drug-concentration. As a cut-
off, we scored as positive any duplex with a monopole to
interphase ratio of one standard deviation or more above the
mean. Re-testing data for the suppressor screen, where the drug
was used at a saturating concentration, was less noisy. Here, any
duplex with a monopole to total nuclei ratio at least two standard
deviations below the mean scored positive.
Long-term Timelapse Microscopy of Suppressor Hits
HeLa H2B-GFP cells were reverse transfected with individual
siRNA duplexes or pools (both at 15 nM final concentration) in 96
well glass bottom plates (MatTek P96G-0-5-F). 24 hours after
transfection, K5I was added to the cells, so that the final inhibitor
concentration was 1 uM. To prevent evaporation during imaging,
50 uL of mineral oil was added to each well. Starting immediately
after drug and mineral oil addition, the cells were imaged at 10
minuteintervalsfor48 hoursonanautomated invertedfluorescence
microscope (Nikon TE2000E) fitted with an incubation chamber
and automated focus. Both GFP and phase contrast images were
Figure 3. Examples of chromosomal phenotypes in the screening assay. All cells were grown in 384-well plates and treated according to the
primary screen assay protocol outlined in Figure 2 and described in Materials and Methods. These samples were all transfected with a non-targeting
siRNA duplexes. (A) Interphase cells and (B) Mitotic cells selected from control wells undergoing normal cell cycle progression; no Kinesin 5 inhibitor
(K5I) added. (C) Monopolar spindles formed in the presence of 1 uM K5I. (D) Analysis of cells treated with 1 uM K5I after 48 hours.
doi:10.1371/journal.pone.0007339.g003
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imaging. For each siRNA pool and duplex reagent tested, 50–100
cells were scored visually for phenotypic changes during imaging.
Taxol and Nocodazole Assays
HeLa H2B-GFP cells were reverse transfected by hand with
individual siRNA duplexes and pools (both at 10 nM final
concentration) in 384 well plates (Corning Costar #3712). 24 hours
after transfection, cells were imaged to determine initial cell density.
Following removal of the transfection mix, media containing either
150 nM of taxol (Paclitaxel) or 300 nM of nocadazole was added to
the transfected cells. Cells were then incubated for an additional
48 hours and imaged for phenotypic changes at 24 hour intervals.
The images generated were scored by visual inspection.
Figure 4. Sample strong hit phenotypes from the K5I Enhancer screen. The nuclei from each time point are color-coded to illustrate their
CellProfiler classifications: yellow=interphase, red=monopolar, blue=unclassified objects. As illustrated in Fig. 2, transfection occurred atT = 0 .( A )
untreatedHeLaH2B-GFPcells, (B)untransfectedcellstreatedwith60 nM K5I,(C) mocktransfectedcellstreatedwithHiPerFect transfection reagentan dn o
K5I. Inpanels D–F, 60 nM K5Iwas added tocells 24 hours after transfectionwith(D)non-targetingsiRNA,orsiRNAsdirectedagainst (E)PLK1 or(F) AURKA.
doi:10.1371/journal.pone.0007339.g004
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Concept of the screen
Our goal was to find proteins that, when their levels were
reduced, made cells either more, or less, sensitive to small molecule
inhibition of Kinesin-5. We hoped to find proteins that modified
cell responses to the drug at the level of mitotic arrest, and also at
the level of apoptosis following mitotic arrest, though in practice
our screen was more effective for finding the former. The concept
was to pre-treat cells with siRNAs targeting one protein, then to
add drug at either a low concentration, scoring for enhancement
of the drug effect, or at a high concentration, scoring for
suppression. We elected to omit a no drug arm to save on
reagents, and distinguished true enhancers from siRNAs that
scored without drug in follow-up assays. The drug response plays
out over several days in unsynchronized cells. At ,24 hours after
adding drug there is a peak in mitotic arrest, and at ,48 hours a
peak in apoptosis [8,9]. We therefore sought an assay that allowed
scoring the response at multiple time-points.
Strategy for Assay Development
We chose high content cell imaging to read out our screening
assay, an information rich method that facilitated monitoring of
multiple phenotypes. We then considered whether to perform a
fixed endpoint or time-lapse assay. Typically, an imaging screen
for mitotic phenotypes would be performed as a fixed endpoint
assay in microplates with immunofluorescence staining for DNA
and indicators of mitotic arrest and perhaps also apoptosis [20].
The advantage of this method lies in ease of image analysis; with
antibodies to different cell-cycle states, classification of cell
phenotypes is straightforward. However, fixed endpoint imaging
would limit our ability to quantify both the mitotic arrest and
apoptosis responses, since they are separated by ,24 hours. Other
potential drawbacks of a fixed endpoint immunofluorescence
assays include the cost of antibodies as well as potential loss of
weakly adherent mitotic cells and distortion of cellular structures
during fixation. Hence, a live cell time-lapse assay is, in principle,
ideal for characterizing the effects of siRNAs that perturb cell
division. However, time-lapse imaging across a whole genome
screen is technically challenging. One approach was a miniatur-
ized RNAi delivery system, in which cells were plated onto
individually spotted siRNA transfection mixes, resulting in
localized solid-phase transfection [14]. However, this approach
required specialized instrumentation and time-consuming analysis
techniques, and generated enormous amounts of data.
We developed a compromise strategy, intermittent live cell
imaging. By imaging the same wells at several time points, we
benefited from the ability to score the same wells immediately
before drug, during peak mitotic arrest (,24 hours in drug) and
peak apoptosis (,48 hours in drug), but can still use relatively
standard image collection and analysis methods developed for
fixed cells. This sparse time-lapse strategy should be useful for any
assay where cell responses play out over a few days.
HeLa cells were chosen for the assay because they are easily
transfected and a line expressing Histone H2B-GFP was available
(Kanda et al., 1998, kind gift of Randy King, HMS). The cell
phenotypes we needed to score have unique nuclear morphologies
(interphase nuclei vs. mitotic chromosomes). Recent advances in
computational methods have proven effective at using a single
nuclear channel to quantify these phenotypes [21,22]. One
disadvantage of H2B-GFP is that the expression level is not
constant from cell to cell, so intensity measures cannot be readily
compared between cells, as they can for DNA staining with DAPI
or Hoechst.
Image analysis
Figure 3 shows examples of our image analysis methods. A cell
in interphase (Fig. 3A) displays a relatively weak and even
fluorescence signal resembling an ellipse with a smooth boundary.
In bipolar mitotic spindles (Fig. 3B), condensed chromosomes line
up in a metaphase plate, displayed as bright oblong objects under
the microscope. Cells arrested in mitosis from treatment with K5I
(Fig. 3C) or knockdown of certain siRNAs, have a characteristic
monopolar spindle phenotype as previously reported [5]. The
strong fluorescent signal arises from chromosomes condensed but
scattered from the center of the cell, sometimes forming a ring.
The image analysis program CellProfiler Analyst [22] was used
to perform machine learning based iterative training to determine
the top 30 descriptors for each nuclear phenotype. For example, a
monopolar mitotic cell displayed a characteristic spotted texture
due to misaligned chromosomes. This property is quantified by top
descriptors such as small form factor (defined as 4*pi*Area/
Perimeter
‘2), due to the rough edge resulting from chromatin
radiating from the cell center, and large standard deviation of
intensity, caused by chromosome condensation and overlap in the
z-dimension.
Interphase nuclei display relatively uniform intensities, a
property that allows straightforward detection by the descriptors
with 95% accuracy. While larger intensity variations are observed
between monopolar cells due to their slightly elevated focal plane,
the accuracy of the descriptors is between 75–90% depending on
image quality. Although bipolar mitotic spindles were another
major phenotype observed in the screen with highly accurate
descriptors, its classification was omitted due to uncertainty
introduced by the relatively short duration of this phenotype.
Some cell density variation was observed after cells were plated
with the Matrix WellMate. The distribution followed a Gaussian
distribution slightly skewed to the right. The cell count cut-off for
the step function in our formula to calculate Enhancer/Suppressor
scores was set to 100, which excluded 251 (1.2%) and 362 (1.7%)
low cell count wells from the enhancer and suppressor arms of the
whole genome respectively.
To classify the phenotypes produced by each siRNA and to rank
genes for further follow-up, data from CellProfiler were used to
calculate Enhancer or Suppressor scores for each siRNA as
described in detail in Materials and Methods. Based on these
scores, the siRNAs were then prioritized for follow-up work. For
secondary screening, we decided to follow up on genes in the top
2% of the Enhancer score list and bottom 2% of the Suppressor
score list. Visual inspection was conducted on the images
corresponding to these genes to eliminate false positives resulting
from technical issues such as variation in focusing and/or exposure
time.
Enhancer Screen – Low Kinesin5 Inhibitor Concentration
Twenty-four hours after transfection, 60 nM of Kinesin-5
inhibitor was added to the cells to screen for siRNA enhancers
of K5I activity. Based on pilot experiments, K5I administered at
60 nM induced no obvious increase in monopolar spindles. As
shown in Figure 4, siRNAs that caused an increase in the number
of monopolar spindles were easily identified. Cells treated with
60 nM K5I alone showed little difference to untreated cells
(Figure 4A, B), while a hit phenotype demonstrated extensive
monopolar metaphase arrest followed by apoptosis at subsequent
time points (Figure 4E, F). To save time and money, we did not
run a no-drug arm in the primary screen. Thus, many of our
preliminary ‘‘enhancers’’ were expected to be siRNAs that cause
mitotic arrest even in the absence of drug. These were
siRNA Modulators of K5I
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compared siRNA effects in low drug and zero drug.
A primary screen of 21,121 siRNA pools targeting most genes in
the human genome identified 336 (1.6%) siRNAs that caused a
significant increase in monopolar mitotic arrest in 60 nM K5I.
Each pool targeted one gene and contained 4 individual siRNA
duplexes. To confirm the K5I enhancer phenotypes, all four
individual siRNAs from each preliminary screening positive pool
were re-tested in the original assay, in duplicate. We found that at
least one of four of the siRNA duplexes recapitulated the primary
screen phenotype in 150 (45%) of the 336 pools followed-up in this
way. Sixty-one (18%) of the positive pools confirmed with at least 2
out of 4 duplexes scoring per pool (Figure 5A, see Table S1 for the
gene list).
To identify and eliminate siRNAs that arrest cells in mitosis
independent of low-dose K5I treatment and are thus not true K5I
enhancers, we monitored siRNA-induced mitotic arrest in the
absence of drug for 90 of the 150 genes for which at least one out
of four individual duplexes were shown to enhance K5I activity.
We chose these 90 siRNAs based on their relatively strong
enhancer phenotypes. siRNAs for 38 of the 90 genes were found to
cause arrest of cells in mitosis in the absence of K5I treatment (see
Table S1 for details). We also tested individual siRNA duplexes
and pools for these 90 genes with a second, structurally diverse
Kinesin-5 inhibitor from Merck Serono, used at sub-threshold
concentrations, and found very similar results to our primary K5I
results, confirming the specificity of the enhancer effect with
respect to drug mechanism: for 87 out of 90 genes at least one
siRNA duplex scored positive with both K5I inhibitors (30 out of
90 had one common positive siRNA duplex, 35 out of 90 had two
common positive duplexes, 18 out of 90 had three common
positive duplexes, and 4 out of 90 had four common positive
duplexes.
Among the genes targeted by siRNAs that score as K5I
enhancers, we found numerous genes involved in regulation of
mitosis and cytokinesis. Some of these, including PLK1, STK6
(Aurora A Kinase, AURKA), SGOL1 (shugoshin), CDCA5
(sororin), CKAP5 (cytoskeleton associated protein, CH-TOG),
and KIF11 (the target of our test drug), caused some increase in
the fraction of cells in monopolar mitotic arrest with siRNA
knockdown alone. These are all proteins known to play essential
roles in mitosis, which, if completely knocked down, should on
their own cause very strong mitotic arrest. Thus, while they score
as K5I enhancers in the screen, they are better thought of as
essential mitotic proteins. We surmise that the siRNA knockdown
is incomplete in most cases, and that low drug concentrations have
an effect on mitotic phenotype that is additive with partial loss of
protein. This consideration complicated analysis of the enhancer
siRNAs, and we therefore prioritized K5I suppressor siRNAs for
further analysis. A complete list of the K5I enhancer siRNAs
identified in our screen is provided in Table S1.
Suppressor Screen – High Kinesin5 Inhibitor
Concentration
For the suppressor screen, transfected cultures were treated with
1 uM K5I, which causes 80–90% of cells to accumulate in
monopolar mitosis after 24 hours of drug treatment (Figure 6B).
After 48 hours in high concentrations of K5I (72 hours after
transfection), cell density begins to drop due to subsequent
apoptosis [8]. In our screen, a suppressor hit phenotype was
identified by decreased monopolar mitotic arrest after 24 hours in
K5I (48 hours after transfection), or an increased cell survival ratio
after 48 hours in K5I (72 hours after transfection). Both
phenotypes could correspond to decreased mitotic arrest, and/or
decreased or earlier apoptosis (Figure 6E, F).
Primary screening revealed 337 (1.6%) potential suppressor
siRNA pools. In secondary screening of individual siRNA duplexes
(4 duplexes/siRNA pool), 198 (59%) of the pools that scored as
positive in the primary screen retested in duplicate with at least 1
Figure 5. Breakdown of results for individual siRNA duplexes from preliminary hits for the K5I enhancer (A) and suppressor (B)
screens. The slices of each pie chart indicate the percent of genes for each screen for which 4/4, 3/4, 2/4, 1/4, or 0/4 of the individual siRNA duplexes
reproduced the enhancer or suppressor phenotype observed for the corresponding siRNA pool. For the enhancer screen, 4 individual siRNA duplexes
for each of 336 siRNA pools that scored as hits in the primary screen were tested in the same assay as used for the primary screen. For the suppressor
screen, the individual duplexes for each of 337 siRNA pools were tested.
doi:10.1371/journal.pone.0007339.g005
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with at least 2 out of 4 duplexes scoring per pool (Figure 5B, see
Table S1 for the gene list).
False positives due to ‘‘off-target’’ effects of RNAi are a
notorious problem in siRNA screens in human cells with current
technology, and no completely satisfactory method is yet
available to eliminate them. We chose the simple expedient
strategy of prioritizing the 31 genes for which 4/4 or 3/4
individual siRNA duplexes demonstrated the K5I suppressor
phenotype in the secondary screen. This should enrich for true
positives, though it will no doubt eliminate many. We added one
other gene, KATNB1 (a subunit of the microtubule severing
enzyme Katanin) that scored with 2/4 duplexes, because of its
interesting function.
Figure 6. Sample strong hit phenotypes from the K5I Suppressor screen. Nuclei from each time point are color-coded to illustrate their
CellProfiler classifications: yellow=interphase, red=monopolar, blue=unclassified objects. As illustrated in Fig. 2, transfection occurred at T=0. (A)
untreated HeLa H2B-GFP cells, (B) untransfected cells treated with 1 uM K5I, and (C) mock transfected cells treated with HiPerFect transfection
reagent and no K5I. In panels D–F, 1 uM K5I was added to cells 24 hours after transfection with (D) non-targeting siRNA, or siRNAs directed against (E)
TTK or (F) Bub3.
doi:10.1371/journal.pone.0007339.g006
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potentially be suppressed by multiple mechanisms, and we used
time-lapse imaging to classify the 32 prioritized primary hits by
phenotype. HeLa H2B GFP cells were transfected with the four
individual duplexes, and also the pool of 4, at 15 nM total siRNA,
a lower concentration than the primary screen to further select for
on-target effects. 24 hours later 1 mM K5I was added, and images
were collected every 10 minutes for 48 hours using an automated
inverted microscope fitted with an incubation chamber. Movies
were scored by visual inspection for three aspects of phenotype:
entry into mitosis, time in mitosis, and whether cells divided after
exit from mitosis, or simply flattened out due to failed cytokinesis.
Visual inspection was used to identify genes for which at least 2
siRNAs had a strong phenotype (15 genes), and for preliminary
classification. The data in Figures 7 and 8 corresponds to these
strong phenotype genes.
By visual inspection, we were able to divide our hits into three
phenotypic classes: I) failure to enter mitosis, II) brief mitotic arrest
without cytokinesis, and III) brief mitotic arrest with cytokinesis.
We will refer to category III siRNAs as ‘‘true suppressors.’’ The
Figure 7. Results of time-lapse experiments to examine duration of mitotic arrest and percent of cells entering cytokinesis after
treatment with K5I suppressor siRNAs. HeLa H2B-GFP cells were transfected with siRNA pools and individual siRNA duplexes directed against
the indicated genes or with a non-targeting control siRNA. ‘‘Mock’’ cells were treated with HiPerFect transfection agent in the absence of siRNA.
24 hours after transfection, K5I was added to all of the samples, so that the final inhibitor concentration was 1 uM. Cells were imaged at 10 minute
intervals for 48 hours on an automated inverted fluorescence microscope and automated focus. 50–100 cells from each condition were scored by
visual inspection for (A) the average duration of mitosis in the population, and (B) the percent of cells going through cytokinesis upon exit from
mitosis. For each of the genes shown, both the siRNA pool and the individual siRNA duplexes were observed to cause the same phenotypes, but only
data for the siRNA pools is graphed here.
doi:10.1371/journal.pone.0007339.g007
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ribonucleotide reductase that is essential for progression through
S-phase. Blocking cells in S-phase was expected as a mechanism
for lowering the mitotic index in K5I. We expected many such
hits, but only RRM2 passed all our prioritization criteria, probably
because cells would have had to arrest within ,12 hours of
addition of siRNA treatment, which would select for very unstable
and/or dose-sensitive proteins. To measure the penetrance of the
siRNA phenotypes for categories II and III, we scored the average
duration of mitosis arrest compared to control siRNA (Figure 7A),
and the fraction of cells leaving mitosis that underwent cytokinesis
(Figure 7B). These data were collected from the movie that showed
the strongest phenotype for the 4 single siRNAs or the pool; in
many cases the pool was the strongest, and in all cases more than
one movie showed the same phenotype. All 15 genes exhibited
mitotic arrest durations of less ,16 hours for either the pool or the
single strongest oligo, and for most of them it was ,4 hours, as
compared to .20 hours in control siRNA. Scoring for the fraction
of cells that underwent cytokinesis approximately divided the
genes into two groups. Using 10% cytokinesis as an arbitrary
dividing line, siRNAs for 3 genes rescued cytokinesis (true
suppressor phenotype, category III), while 12 suppressed mitotic
arrest, but did not rescue cytokinesis (category II).
Drug specificity
To further categorize the genes that shortened mitotic arrest, we
tested their ability to suppress mitotic arrest caused by Paclitaxel
(which blocks microtubule dynamics) and nocodazole (which
depolymerizes microtubules). Both drugs arrest cells in mitosis by
activating the spindle assembly checkpoint (SAC), like K5I. We
tested all the genes in Figure 7, except KATNB1. HeLa H2B GFP
cells were transfected with individual siRNAs and the pool of 4,
and 24 hours later we added 150 nM taxol or 300 nM
nocodazole. Twenty-four hours after that, cells were fixed, and
the fraction arrested in mitosis under these conditions was scored
by visual inspection (Figure 8A). We quantified only the pool, but
visually confirmed that at least 2 of the individual oligos scored
with the same phenotype in all cases. In Paclitaxel-treated wells
where the mitotic arrest was suppressed, we observed a large
percentage of cells in interphase with multiple micronuclei. This
phenotype is characteristic of slippage out of taxol-induced arrest
[23]. This experiment appeared to cleanly divide the genes into
Figure 8. Drug specificity and final phenotypes. A: Drug specificity tests. HeLa H2B-GFP cells were transfected with siRNA pools as indicated, or
‘‘Mock’’ transfected in the absence of siRNA. 24 hours after transfection, medium containing either 150 nM of taxol or 300 nM of nocadazole was
added to all of the samples. Cells were then incubated for an additional 24 hours and imaged for phenotypic changes. The pools were scored visually
for cells in mitotic arrest, and this value was quantified for the pool by counting .100 cells. (B) Phenotypic categorization of hits on the basis of data
in Figure 7 and 8A. Category I) failure to enter mitosis, II) brief mitotic arrest without cytokinesis, and III) brief mitotic arrest with cytokinesis (true
suppressors). Shown in bold are 5 expected genes, 4 known SAC genes and KifC1, which is a known true suppressor of loss of Kinesin-5 function [28].
doi:10.1371/journal.pone.0007339.g008
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nocodazole in addition to K5I, and those that only suppressed
K5I. All the annotated SAC genes suppressed all the drugs, as
expected. Two other genes scored with this phenotype, PMAIP1
and NPC2, and these were also notable for very short mitotic
arrest durations (Figure 7A). The 3 true suppressors (category III)
failed to suppress taxol and nocodazole. A number of category II
genes failed to suppress taxol and nocodazole, including all those
that less effectively suppressed K5I mitotic arrest as scored by
duration (Figure 7A), but also two that strongly suppressed K5I,
TRIM28 and EFTUD2. On the basis of this extra data, we
divided category II into two, SAC defect (all drugs) and SAC
defect (K5I) (Figure 8B).
Mechanistic implications
An important caveat in discussing any of the new genes in
Figure 8 is the question of specificity. Although we tried to select
for on-target effects by requiring at least 3 out of 4 oligos to score,
we suspect some of our hits may still be false positives. Further
work, including monitoring protein levels after knockdown and
rescue with RNAi-resistant transgenes, is required to more
rigorously test their specificity.
In the SAC defect (all drugs) category, we recovered 4 known
SAC genes: TTK (Mps1 kinase), BUB3, BUB1B, and MAD2L1.
We missed a few other well-annotated SAC genes, including
MAD1, presumably because the knockdown was insufficient in our
time window. Two other genes scored with the same phenotype,
NPC2 and PMAIP1. NPC2 is an endosome protein implicated in
cholesterol transport [24], and PMAIP1 (also known as NOXA) is
a BH3-only pro-apoptotic protein that stimulates apoptosis by
interacting with Bcl2 related proteins [25]. Because of its possible
role in linking mitotic arrest to apoptosis, we performed limited
follow-up work on PMAIP1/NOXA. Different siRNA oligos for
this gene exhibited different strengths of phenotypic effect as
suppressors of mitotic arrest. In addition to knocking down
PMAIP1 protein levels, we noted that the two siRNAs (#2 and
#3) that inhibited mitotic arrest most effectively also caused partial
knockdown of Mad2 protein levels (Figure S1), though they did
not affect expression of another checkpoint protein BubR1 (data
not shown). Thus it is possible that the K5I suppressor effect of the
PMAIP1 siRNA reagents are due to an off-target knockdown of
Mad2 by the PMAIP1 siRNAs. Consistent with this, the seed
regions of the PMAIP1 siRNA#2 and #3 each share sequence
identity with different 7 nucleotide stretches of the MAD2L1 39
UTR mRNA sequence (RefSeq NM_002358.3). siRNA seed
region matches to 39 UTR regions are associated with RNAi off-
targets [26,27].
The SAC defect (K5I only) category was unexpected, and the
gene annotations provide little in the way of mechanistic clues.
DONSON is, by sequence, the probable ortholog of the
Drosophila gene humpty dumpty, which has been implicated in
control of DNA replication [26]. RPS25 is a ribosome subunit,
and thus might be a false positive. EFTUD2 is annotated as a
spliceosome component. Knocking down these proteins appears to
suppress SAC activation by K5I, but not by taxol or nocodazole,
yet they do not rescue spindle bipolarity, at least by the criterion of
promoting cytokinesis. This exclusivity for K5Is could be the result
of a more weakly activated SAC by K5I, or that the SAC is
activated in a different way, that requires extra proteins to block
the cell cycle relative to taxol and nocodazole activation of the
SAC. It is also interesting that K5Is do not target the microtubules
themselves, perhaps resulting in SAC-dependent arrest that is
unique at the molecular level compared to microtubule targeting
drugs.
Category III, the true suppressors, were particularly interesting
from a spindle assembly perspective. This phenotype requires that
the cell assemble a normal bipolar spindle even though Kinesin-5
is inhibited, or alternatively, this class might by due to increased
drug efflux or metabolism. KIFC1 (also known as HSET), a
mitotic kinesin that works opposite to Kinesin-5, was expected
with this phenotype, since previous work has demonstrated that
loss of KIFC1 function can rescue spindle bipolarity when
Kinesin-5 function is compromised [28]. The strongest suppressor
was CBX1, a heterochromatin protein. 45% of cells that entered
mitosis underwent cytokinesis in cells treated with this siRNA pool
in the presence of 1 mM K5I (Fig. 7B). This value can be compared
to ,1% cytokinesis in K5I alone, and 3% for TTK siRNA (a
strong Category II hit) in K5I. We tentatively speculate that CBX1
is required for some aspect of kinetochore or chromokinesin
function that normally helps pull the two half-spindles together.
When this function is absent, the forces that collapse the spindle in
K5I are reduced. Another strong suppressor, HINT1, is an
enzyme with phosphoramidase activity that is a tumor suppressor,
and has been implicated in DNA damage repair [28]. Perhaps this
protein also influences the spindle via effects on chromatin
structure.
Summary
Our intermittent imaging approach was effective for identify-
ing siRNA enhancers and suppressors of K5Is that act at the level
of spindle assembly and mitotic arrest, and should be useful for
other cell cycle related screens. It was less effective at identifying
genes that influence apoptotic responses, perhaps because we
were not able to develop a specific score for apoptosis using H2B-
GFP imaging. Characterization of siRNAs that score as K5I
enhancers was complicated by the fact that many of those
siRNAs had some mitotic phenotype on their own, in addition to
acting as enhancers of drug action. However, the enhancer
siRNA hit list is strongly enriched in genes with mitotic functions,
and may reveal other genes not previously implicated in spindle
bipolarization. Our K5I suppressor siRNAs broke fairly cleanly
into 4 phenotypes (Figure 8B). Current RNAi technology is
sufficiently prone to false positives that we make no claims as to
specificity of our hits. Even genes for which4/4 individual siRNA
duplexes scored as hits must be viewed with suspicion until
confirmed by other methods. For example, the possibility that
PMAIP1 scored as a hit due to off-target knockdown of Mad2
levels (Figure S1) is a case in point. We also acknowledge that we
surely missed many genes as false negatives Presumably, our
screen selected for proteins that turn over rapidly and/or whose
effects on their pathway are highly dose-sensitive. Still, we
recovered about half of the well-documented SAC genes, and the
only known true K5I suppressor gene (KIFC1), in the expected
phenotypic categories. Thus, we are confident that at least some
of our others hits are worthy of further exploration, and will open
up new avenues of research into spindle organization and the
SAC.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0007339.s001 (0.15 MB TIF)
Table S1 List of genes with at least one out of four oligos
confirmed in the same assay as used for the primary screen.
Found at: doi:10.1371/journal.pone.0007339.s002 (0.06 MB
XLS)
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